Ty -Jour T1-人类脂多糖模型为系统性和肺部炎症提供了机械和治疗见解JF-欧洲呼吸杂志JO -EUR RESSIR J DO -10.1183/13993003.01298-2019 SP -1901298 AU -BROKS，DANIEL AU -BARL AU -BARL AURA C.Au -Wiscombe，Sarah au -McAuley，Daniel F. au -Simpson，A。JohnAu -Rostron，Anthony J. Y1-2020/01/01 Ur -http：//www.qdcxjkg.com/content/content/early/2020/2020/03/17/13993003.01298-2019.Abstract N2-炎症是败血症和急性呼吸遇险综合征（ARDS）发病机理中的关键特征。败血症和ARDS继续与高死亡率有关。一个关键因素是对人类肺部和全身性炎症早期事件的基本理解，这些事件在临床实践中很难研究，因为它们在患者向医疗服务的介绍之前。脂多糖（LPS）是革兰氏阴性细菌外膜的组成部分，是炎症的触发因素，败血症的宿主反应失调。Human LPS模型为健康的志愿者提供了少量LP，引发了炎症反应，并提供了研究人类早期炎症的窗口。这允许从定义的时间点在受控的，可重复的环境中测试生物/机械洞察力和新的治疗策略。我们回顾了人类LPS模型的使用，重点是研究对静脉内和肺LPS挑战的反应而获得的潜在机械见解。我们讨论可能会影响LP的反应的变量，然后再考虑在设计未来的人类LPS研究时应考虑的因素。Footnotesthis手稿最近已被接受在欧洲呼吸道期刊上发表。它在我们的生产团队复制和排版之前以其公认的形式出版。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Brooks has nothing to disclose.Conflict of interest: Dr. Barr has nothing to disclose.Conflict of interest: Dr. Wiscombe has nothing to disclose.Conflict of interest: Dr. McAuley reports personal fees from Peptinnovate, personal fees from Bayer, grants from NIHR, Wellcome Trust and other funders, personal fees from GlaxoSmithKline, other from GlaxoSmithKline, personal fees from Boehringer Ingelheim, personal fees from SOBI, outside the submitted work; In addition, Dr. McAuley has a patent Patent for novel treatment for ARDS issued to Queen's University Belfast.Conflict of interest: Dr. Simpson has nothing to disclose.Conflict of interest: Dr. Rostron has nothing to disclose. ER -